FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308378589> ?p ?o ?g. }

• W4308378589 abstract "<h3>Background</h3> CD47 is a central part of the innate immune system through its interaction with signal regulatory protein alpha (SIRPα). This interaction is known as the “don9t eat me” signal which inhibits cell phagocytosis by innate immune cells.^1,2 Cancer cells often evade recognition by the hosts’ immune cells through overexpression of CD47, and several anti-CD47 monoclonal antibodies (mAbs) are undergoing development to inhibit this interaction.³ Some anti-CD47 mAbs have been shown to have potential as treatment of human malignancy, but generally only in combination with other chemotherapeutic agents as their functionality primarily is due to the inhibition of the phagocytic signal.^1,4 Here, we characterize CO-1, a novel bifunctional anti-CD47 mAb that is capable of eradicating cancer cells through direct induction of programmed cell death (PCD) as well as by enhancing cancer cell phagocytosis. <h3>Methods</h3> The binding properties of CO-1 to a wide range of cancer cell lines derived from solid and hematological tumors was determined by incubating the cells to FITC-conjugated antibodies, followed by flow cytometry analysis. The induction of PCD after treatment with different anti-CD47 mAbs at different time points was determined by Annexin V staining.⁵ The enhancement of tumor cell phagocytosis induced by CO-1 was determined by co-culturing DiO-labelled RAW264.7 macrophages with CFSE-labelled target cell lines. Double-positive DiO-RAW264.7 and CFSE-target cells indicated phagocytosed cells. Xenograft models were established by injecting lentivirally transduced cancer cells into NOD-<i>scid</i> IL2Rγ^null (NSG) mice. The lentiviral vector contained sequences for firefly luciferase and enhanced green fluorescent protein.⁶ <h3>Results</h3> CO-1 binds to cancer cells with high efficiency and induces rapid (within 3 hours) and profound cell death in several cell lines derived from human hematological and solid tumors. No direct correlation was evident between CD47 expression and PCD response. In a xenograft model of B cell precursor acute lymphoblastic leukemia (BCP-ALL) in NSG mice, the mice were rapidly cured of their tumor even after only two injections of CO-1 as monotherapy. This demonstrates the PCD potency of CO-1 towards human tumor cells directly. Next, we determined the ability of CO-1 to block the “don9t eat me” interaction and found that CO-1 potently and significantly enhanced tumor cell phagocytosis, even in cell lines that previously had responded less favorably with PCD to CO-1 treatment. <h3>Conclusions</h3> CO-1 is a new and unique bifunctional anti-CD47 mAb that eradicates cancer cells by two mechanisms of action: 1)by direct induction of PCD, and 2)by enhancing cancer cell phagocytosis. <h3>References</h3> J Huang, F Liu, C Li, X Liang, C Li, Y Liu, Z Yi, L Zhang, S Fu, Y Zeng. Role of CD47 in tumor immunity: a potential target for combination therapy. <i>Scientific Reports</i> 2022;<b>12</b>. 10.1038/s41598-022-13764-3. S Kaur, JS Isenberg, DD Roberts. CD47 (Cluster of Differentiation 47). <i>Atlas Genet Cytogenet Oncol Haematol</i> 2021;<b>25</b>:83–102. Z Jiang, H Sun, J Yu, W Tian, Y Song. Targeting CD47 for cancer immunotherapy. <i>J Hematol Oncol</i> 2021;<b>14</b>:180. 10.1186/s13045-021-01197-w. Y Huang, Y Ma, P Gao, Z Yao. Targeting CD47: the achievements and concerns of current studies on cancer immunotherapy. <i>Journal of Thoracic Disease</i> 2017;<b>9:</b>E168–E174. 10.21037/jtd.2017.02.30. I Vermes, C Haanen, H Steffens-Nakken, C Reutellingsperger. A novel assay for apoptosis Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. <i>Journal of Immunological Methods</i> 1995;<b>184:</b> 39–51. https://doi.org/10.1016/0022-1759(95)00072-I. S Bomken, L Buechler, K Rehe, F Ponthan, A Elder, H Blair, CM Bacon, J Vormoor, O Heidenreich. Lentiviral marking of patient-derived acute lymphoblastic leukaemic cells allows in vivo tracking of disease progression. <i>Leukemia</i> 2013;<b>27:</b>718–721. 10.1038/leu.2012.206. <h3>Ethics Approval</h3> The study was conducted under adherence with the Declaration of Helsinki. Animals were kept under appropriate housing conditions with food and water ad libitum. All animal experiments were approved by the Norwegian Food Safety Authorities." @default.
• W4308378589 created "2022-11-11" @default.
• W4308378589 creator A5032018444 @default.
• W4308378589 creator A5037113825 @default.
• W4308378589 creator A5050281255 @default.
• W4308378589 creator A5053648084 @default.
• W4308378589 creator A5091651229 @default.
• W4308378589 date "2022-11-01" @default.
• W4308378589 modified "2023-09-25" @default.
• W4308378589 title "494 CO-1: A novel potent dual function anti-CD47 antibody for cancer therapy" @default.
• W4308378589 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0494" @default.
• W4308378589 hasPublicationYear "2022" @default.
• W4308378589 type Work @default.
• W4308378589 citedByCount "0" @default.
• W4308378589 crossrefType "proceedings-article" @default.
• W4308378589 hasAuthorship W4308378589A5032018444 @default.
• W4308378589 hasAuthorship W4308378589A5037113825 @default.
• W4308378589 hasAuthorship W4308378589A5050281255 @default.
• W4308378589 hasAuthorship W4308378589A5053648084 @default.
• W4308378589 hasAuthorship W4308378589A5091651229 @default.
• W4308378589 hasBestOaLocation W43083785891 @default.
• W4308378589 hasConcept C121608353 @default.
• W4308378589 hasConcept C136449434 @default.
• W4308378589 hasConcept C153911025 @default.
• W4308378589 hasConcept C159654299 @default.
• W4308378589 hasConcept C160448771 @default.
• W4308378589 hasConcept C185592680 @default.
• W4308378589 hasConcept C190283241 @default.
• W4308378589 hasConcept C203014093 @default.
• W4308378589 hasConcept C2780104668 @default.
• W4308378589 hasConcept C31573885 @default.
• W4308378589 hasConcept C40677261 @default.
• W4308378589 hasConcept C502942594 @default.
• W4308378589 hasConcept C542903549 @default.
• W4308378589 hasConcept C54355233 @default.
• W4308378589 hasConcept C553184892 @default.
• W4308378589 hasConcept C55493867 @default.
• W4308378589 hasConcept C81885089 @default.
• W4308378589 hasConcept C86803240 @default.
• W4308378589 hasConcept C8891405 @default.
• W4308378589 hasConcept C95444343 @default.
• W4308378589 hasConcept C96232424 @default.
• W4308378589 hasConceptScore W4308378589C121608353 @default.
• W4308378589 hasConceptScore W4308378589C136449434 @default.
• W4308378589 hasConceptScore W4308378589C153911025 @default.
• W4308378589 hasConceptScore W4308378589C159654299 @default.
• W4308378589 hasConceptScore W4308378589C160448771 @default.
• W4308378589 hasConceptScore W4308378589C185592680 @default.
• W4308378589 hasConceptScore W4308378589C190283241 @default.
• W4308378589 hasConceptScore W4308378589C203014093 @default.
• W4308378589 hasConceptScore W4308378589C2780104668 @default.
• W4308378589 hasConceptScore W4308378589C31573885 @default.
• W4308378589 hasConceptScore W4308378589C40677261 @default.
• W4308378589 hasConceptScore W4308378589C502942594 @default.
• W4308378589 hasConceptScore W4308378589C542903549 @default.
• W4308378589 hasConceptScore W4308378589C54355233 @default.
• W4308378589 hasConceptScore W4308378589C553184892 @default.
• W4308378589 hasConceptScore W4308378589C55493867 @default.
• W4308378589 hasConceptScore W4308378589C81885089 @default.
• W4308378589 hasConceptScore W4308378589C86803240 @default.
• W4308378589 hasConceptScore W4308378589C8891405 @default.
• W4308378589 hasConceptScore W4308378589C95444343 @default.
• W4308378589 hasConceptScore W4308378589C96232424 @default.
• W4308378589 hasLocation W43083785891 @default.
• W4308378589 hasOpenAccess W4308378589 @default.
• W4308378589 hasPrimaryLocation W43083785891 @default.
• W4308378589 hasRelatedWork W2023944088 @default.
• W4308378589 hasRelatedWork W2053279347 @default.
• W4308378589 hasRelatedWork W2059347528 @default.
• W4308378589 hasRelatedWork W2339482712 @default.
• W4308378589 hasRelatedWork W2348629719 @default.
• W4308378589 hasRelatedWork W2368460920 @default.
• W4308378589 hasRelatedWork W2380360044 @default.
• W4308378589 hasRelatedWork W2386605958 @default.
• W4308378589 hasRelatedWork W2428228634 @default.
• W4308378589 hasRelatedWork W2768951490 @default.
• W4308378589 isParatext "false" @default.
• W4308378589 isRetracted "false" @default.
• W4308378589 workType "article" @default.